Cytosorbents Corp (CTS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corporation on August 10, 2022. The filing discloses the approval of annual base salaries and incentive equity awards for the company's executive officers by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on executive compensation details.
Material Changes and Compensation Details
On August 10, 2022, the Compensation Committee approved the following compensation packages for Fiscal Year 2022:
- Base Salaries: No increase (0.0%) from the prior year, effective January 1, 2022.
- Phillip P. Chan, MD, PhD (CEO): $482,851
- Vincent J. Capponi (President & COO): $424,000
- Kathleen P. Bloch (CFO): $370,428
- Efthymios N. Deliargyris, MD (CMO): $408,100
- Equity Awards: Grants included Time-Vesting Stock Options, Restricted Stock Units (RSUs), and Milestone-Vesting Stock Options.
- Strike Price: $1.95 per share (closing price on grant date).
- Term: 10 years for time-vesting options.
- Vesting Schedules: Time-vesting options vest quarterly over three years; RSUs vest annually over two years (with specific Change in Control provisions for Dr. Deliargyris).
Guidance, Outlook, and Milestones
Milestone-vesting stock options are contingent upon achieving specific operational and financial targets by December 31, 2025. Key milestones include:
- Milestone 1: FDA approval for the product DrugSorb.
- Milestone 2: Achievement of $80 million or more in annual ex-U.S. sales.
- Milestone 3: Achievement of $20 million or more in annual U.S. sales.
- Milestone 4: Achievement of U.S. GAAP breakeven.
- Additional Milestone (CMO only): A second FDA approval for DrugSorb.
The filing does not contain specific forward-looking financial guidance, risk factors, or management commentary beyond the description of these compensation milestones.
Investor Verification Checklist
- Verify the current stock price relative to the $1.95 strike price of the newly granted options.
- Monitor progress toward the four key milestones (FDA approval, sales targets, breakeven) to assess potential equity dilution.
- Review the company's latest 10-K or 10-Q for actual revenue and cash flow figures, as this 8-K does not contain financial performance data.
- Confirm the status of the DrugSorb FDA application to evaluate the likelihood of Milestone 1 vesting.